Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.53 |
| ▸ | PDE11A | Q9HCR9 | 11/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13919447 | 1.00 | PDE4B (0.53) | PDE4BPDE11APDE10A | |
| SCHEMBL12923213 | 0.95 | PDE4B (0.48) | PDE4BPDE11APDE10A | |
| SCHEMBL12464378 | 0.94 | PDE4B (0.54) | PDE4BPDE11APDE10A | |
| SCHEMBL8092859 | 0.94 | PDE4B (0.48) | PDE4BPDE11APDE10A | |
| SCHEMBL13919567 | 0.93 | PDE4B (0.54) | PDE4BPDE11APDE10A | |
| SCHEMBL152335 | 0.92 | PDE4B (0.54) | PDE4BPDE11APDE10A | |
| SCHEMBL16393762 | 0.92 | PDE4B (0.54) | PDE4BPDE11APDE10A | |
| SCHEMBL16393759 | 0.92 | PDE4B (0.54) | PDE4BPDE11APDE10A | |
| SCHEMBL152336 | 0.92 | PDE4B (0.54) | PDE4BPDE11APDE10A | |
| SCHEMBL12705538 | 0.92 | PDE4B (0.45) | PDE4BPDE11APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985860-B2 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | SCHERING CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-7919505-B2 | Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound | SCHERING CORPORATION (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919505-B2 | Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound | SCHERING CORPORATION (US) | 2011-04-05 | — | — | US | disclosed |
| US-20110003780-A1 | HYDROGEN CHLORIDE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND AND A PROCESS FOR THE PRODUCTION THEREOF | SCHERING CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003780-A1 | HYDROGEN CHLORIDE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND AND A PROCESS FOR THE PRODUCTION THEREOF | SCHERING CORPORATION (US) | 2011-01-06 | — | — | US | disclosed |
| US-20100324295-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 5-QUINOLYL-OXAZOLES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SCHERING CORPORATION | 2010-12-23 | — | — | US | disclosed |
| US-20100324295-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 5-QUINOLYL-OXAZOLES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SCHERING CORPORATION | 2010-12-23 | — | — | US | disclosed |
| US-7511062-B2 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511062-B2 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080045718-A1 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | MERCK SHARP & DOHME CORP. | 2008-02-21 | — | — | US | disclosed |
| US-20080027101-A1 | XINAFOATE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND | SCHERING CORPORATION | 2008-01-31 | — | — | US | disclosed |
| US-20080027101-A1 | XINAFOATE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND | SCHERING CORPORATION | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324295-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 5-QUINOLYL-OXAZOLES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | PDE4B, PDE4A, PDE3B | PDE4B 1/4885PDE11A 26/4885PDE10A 18/4885 |
| US-20110003780-A1 | HYDROGEN CHLORIDE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND AND A PROCESS FOR THE PRODUCTION THEREOF | OXA1L, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH2 | PDE4B 1971/4885PDE11A 2442/4885PDE10A 1084/4885 |
| US-20080027101-A1 | XINAFOATE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND | XDH, UPF1, NOX5 | PDE4B 461/4885PDE11A 1277/4885PDE10A 1112/4885 |
| US-20080045718-A1 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | PDE4B, PDE4A, PDE3B | PDE4B 1/4885PDE11A 31/4885PDE10A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.